Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02160769
Other study ID # R1075/90/2013
Secondary ID 2013/851/A
Status Completed
Phase
First received
Last updated
Start date November 2013
Est. completion date July 2020

Study information

Verified date October 2020
Source Singapore National Eye Centre
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The investigators study aims to capture the objective effects of pterygium surgery on tear layer lipid thickness and the tear layer. Previous objective studies of the tear film has been limited to corneal staining grading, tear break up time and Schirmer's test which have been shown to poor to moderate repeatability. The effect of pterygiums on tear layer lipid thickness (LLT) has not previously been explored. With the LipiView Ocular Surface Interferometer, the investigators have the ability to assess the optical coherence interference pattern produced by light reflected off the tear film in a safe and non-invasive manner. Software analysis of the image then measures the tear LLT which can be used to objectively quantify the diagnosis of lipid-deficient dry eye.


Description:

Pterygium is a condition characterized by abnormal conjunctival growth on the cornea and is particularly prevalent in tropical climates. In severe circumstances, it may lead to visual loss by obscuration of the visual axis and inducing corneal astigmatism (1). It is often also associated with dry eye symptoms and studies have previously shown some correlation with shortened tear break up time (TBUT)(2) but not Schirmer's Test (3). Schirmer's Test, corneal staining and TBUT are often used to investigate symptoms of dry eyes but the diagnosis and assessment is often difficult due to the poor repeatability of the tests(4). Treatments for dry eyes often rely on patient's subjective symptomatic improvements as a measure of outcome although no literature has been published of subjective symptoms for pterygium patients. The effects of pterygium surgery and tear lipid layer thickness has also not been studied. The LipiView Ocular Surface Interferometer is a HSA-approved imaging device that allows clinicians evaluate the characteristics and thickness of the tear lipid layer thickness (LLT) in a safe and non-invasive manner. The device utilizes white light from a LED source that is directed at the tear film over the inferior corneal region. Reflected light is captured by a high resolution camera and the optical inference pattern is evaluated by software to determine the LLT (5). It also was found to correlate with other dry eye diagnostic tests, such as tear film break-up time (TBUT), Schirmer's test and corneal staining(6,7). LLT is also reported to better correlate with symptoms than other objective dry eye tests(5). LipiView was also capable of detecting a significant change in longitudinal lipid thickness in 10 patients one month after blepharoplasty. A similar result may be obtained from the investigators patients post pterygium surgery. This current study aims to investigate the effects of pterygium surgery on tear lipid layer thickness with LipiView. The results will be compared with the effects of pterygium surgery on TBUT, and corneal staining. The subjective improvement in dry eye symptoms post pterygium surgery will also be studied. Clinical importance This study can provide further data to support pterygium surgery as a role in dry eyes management in an objective and reproducible manner. New data on pterygium and tear lipid layer thickness as well as subjective dry eye symptoms will also be explored. Study Objectives and Purpose The Assesssment of Dry Eye Symptoms, Tear Layer and Tear Layer Lipid Thickness Pre and 1month Post Pterygium Surgery using a LipiView Ocular Surface Interferometer (LipiView) Study design: Prospective study Rationale: Methods: Participants and target sample size Target sample size: 80 40 patients who will be undergoing pterygium surgery will be recruited for this study. Another 40 patients will be recruited from the general ophthalmology (ECS) clinic. These patients are cleared to have no lid disturbances in terms of function or anatomy, and will serve as the "control" group. Permission will be sought from the junior ophthalmologists and the supervising ophthalmologist (in the event of a training list) or from the senior ophthalmologist if he is performing the surgery himself. These patients would have been diagnosed with pterygium and opted for surgical excision and conjunctival autograft. Pre operatively they will complete a simple questionnaire to evaluate any dry eye symptoms. Participants will be examined under the slit lamp for fluorescein dye corneal staining and fluorescein dye tear break up time. The patients will then undergo a LipiView Ocular Surface Interferometer Measurement of Tear lipid layer thickness. Visit schedules Two/Three visits is required for paticipants who are undergoing pterygium surgery. Only one visit is required for normal controls who are recruited from general ophthalmology (ECS) clinic. Duration of study: 10 months. Procedures: 1. Assessment of Dry Eye Symptoms (SANDE) Participants will be asked to score and fill up a dry eye questionnaire that assesses the symptomatic severity and frequency of dry eyes symptoms. • SANDE Questionnaire Consists of 3 questions on frequency and severity. VAS will be applied to evaluate dry eye symptoms as described by Schaumberg et al. (Schaumberg, Gulati et al. 2007). The scores will be recorded separately for frequency and severity of dry eye symptoms. Patients will be asked to mark "X" on a 100mm line that corresponds to the degree of the symptom. A global score will be calculated by multiplying the frequency score by the severity score and taking the square root of the result (to transform back to the original scale). Basic biodata such as age, race, gender will also be recorded. 2. LipiView Ocular Surface Interferometer Measurement of Tear lipid Layer Thickness Prior measuring the tear lipid layer thickness, participants are advised not to: i. instill any eye ointment for at least 24 hours, or ii. instill eye drops or wear contact lenses for 4 hours, or iii. swim in a chlorinated pool, rub their eyes or put on eye cosmetics on the day of the measurement. During the measurement of each eye, the participants place their chins on a chin rest and look at a single white light source for 30 seconds. During this period, participants are encouraged to blink freely at a comfortable rate which the assessor measures the LLT. Similar steps would be taken for the other eye as a control eye. Assessment of fluorescein tear break up time and corneal staining will be conducted only after LipiView LLT measurement. 3. Fluorescein Dye Tear Break-up Time (TBUT) Fluorescein dye is introduced onto the lower eyelid by a wetted fluorescein strip. The tear film will then be observed with blue light using a slit lamp to the point where it breaks. The time from the previous blink to the breaking of the tear film will be recorded to the nearest second. 4. Fluorescein Dye Corneal Staining After fluorescein dye is introduced, the cornea will be examined for green stains indicating epithelial erosion, a sign of damage due to dryness. The number of green stains and their location on the cornea (superior, central, inferior, temporal, nasal fields) will be recorded. 5. Patient will undergo pterygium excision and conjunctival autograft on the prearranged surgery date. 6. Steps 1-4 will be repeated 1 month post operatively. Outcomes: Primary outcome: An increase in tear lipid layer thickness 1 month post pterygium surgery in the operated eye. Statistics: There will be no interim analysis. Analysis will be performed after all the subjects have completed the required visits or have withdrawn from the study. Data will be analysed for sample mean of pre and post-operative questionnaire score, tear break up time, corneal staining and tear lipid layer thickness in both the operated and un-operated eye. The confidence intervals of the pre and post-operative in both the operated and un-operated will be calculated with T-test analysis. Expected outcomes: There should be decreased dry eye symptoms in the operated pterygium eye with a improvement in tear break up time, decreased corneal staining and increase tear lipid layer thickness when compared to pre operative. Potential problems No potential problems are expected for this study. Inclusion Criteria 1. Normal controls or patients with pterygium who have consented for pterygium surgery and are willing to participate in this study Exclusion Criteria 1. Active ocular surface conditions such as infections. 2. Any other specified reason as determined by clinical investigator.


Recruitment information / eligibility

Status Completed
Enrollment 76
Est. completion date July 2020
Est. primary completion date July 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years to 99 Years
Eligibility Inclusion Criteria: - Normal controls or patients with pterygium who have consented for pterygium surgery and are willing to participate in this study Exclusion Criteria: - Active ocular surface conditions such as infections. - Any other specified reason as determined by clinical investigator.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Singapore Singapore Eye Research Institute Singapore Singapore.

Sponsors (1)

Lead Sponsor Collaborator
Singapore National Eye Centre

Country where clinical trial is conducted

Singapore, 

Outcome

Type Measure Description Time frame Safety issue
Primary tear lipid layer thickness An increase in tear lipid layer thickness 1 month post pterygium surgery in the operated eye 1 month
See also
  Status Clinical Trial Phase
Completed NCT06159569 - Performance and Tolerability of the Medical Device LACRIACT N/A
Completed NCT05027087 - The Effect of a Novel Blueberry Supplement on Dry Eye Disease Phase 3
Completed NCT05102409 - An Exploratory Clinical Trial to Assess Safety and Tolerability in Subjects With Dry Eye Disease Phase 2
Completed NCT04081610 - Clinical Trial to Evaluate the Safety and Tolerability of Lagricel® Ofteno Multi-dose Ophthalmic Solution Phase 1
Completed NCT05062564 - Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye N/A
Completed NCT05825599 - PMCF Study to Evaluate Performance and Safety of "HPMC-based Eyedrops" Used to Relieve Dry Eye Symptoms N/A
Completed NCT03418727 - Dry Eye Disease Study With Brimonidine Phase 2
Active, not recruiting NCT04425551 - Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction N/A
Recruiting NCT04527887 - Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease (DEcIDED) Phase 4
Not yet recruiting NCT06379685 - Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface. Phase 1
Active, not recruiting NCT05618730 - Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B Phase 1
Completed NCT04553432 - Dry Eye OmniLenz Application of Omnigen Research Study Phase 4
Recruiting NCT04109170 - Dry Eye Evaluation System Based on Bioinformatics
Completed NCT04105842 - Refitting Daily Disposable Contact Lens Wearers With Dry Eye Disease With A Different Daily Disposable Lens Type N/A
Completed NCT05505292 - Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers Phase 4
Completed NCT04668131 - Study on Curative Effect and Mechanism of Acupuncture on Neuropathic Pain in Dry Eye Disease N/A
Completed NCT06176651 - Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers Phase 4
Completed NCT02235259 - Efficacy and Safety of XG-104 for the Treatment of Dry Eye Phase 2
Not yet recruiting NCT02218827 - Topical Steroid Treatment For Dry Eye N/A
Completed NCT01959854 - Efficacy of Topical 0.2% Xanthan Gum in Patients With Dry Eye N/A